(S)-5-(1-Ethyl-3-(trifluoromethyl-1H-pyrazol-4-yl)-2-(1-(4-methoxypyridin-2-yl)ethyl)-7-((2-methyl-1H-Imidazol-1-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one

ID: ALA5177656

Chembl Id: CHEMBL5177656

PubChem CID: 149503094

Max Phase: Preclinical

Molecular Formula: C28H29F3N6O2

Molecular Weight: 538.57

Associated Items:

Names and Identifiers

Canonical SMILES:  CCn1cc(-c2cc(Cn3ccnc3C)cc3c2CCN([C@@H](C)c2cc(OC)ccn2)C3=O)c(C(F)(F)F)n1

Standard InChI:  InChI=1S/C28H29F3N6O2/c1-5-36-16-24(26(34-36)28(29,30)31)22-12-19(15-35-11-9-32-18(35)3)13-23-21(22)7-10-37(27(23)38)17(2)25-14-20(39-4)6-8-33-25/h6,8-9,11-14,16-17H,5,7,10,15H2,1-4H3/t17-/m0/s1

Standard InChI Key:  ZHJGXPCMCSZPPK-KRWDZBQOSA-N

Alternative Forms

  1. Parent:

    ALA5177656

    ---

Associated Targets(Human)

MV4-11 (7307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
WDR5 Tchem WD repeat-containing protein 5 (979 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOLM-13 (2241 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 538.57Molecular Weight (Monoisotopic): 538.2304AlogP: 5.31#Rotatable Bonds: 7
Polar Surface Area: 78.07Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 7.05CX LogP: 3.96CX LogD: 3.81
Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.32Np Likeness Score: -1.02

References

1. Teuscher KB, Meyers KM, Wei Q, Mills JJ, Tian J, Alvarado J, Sai J, Van Meveren M, South TM, Rietz TA, Zhao B, Moore WJ, Stott GM, Tansey WP, Lee T, Fesik SW..  (2022)  Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.,  65  (8.0): [PMID:35436124] [10.1021/acs.jmedchem.2c00195]
2. Teuscher KB, Meyers KM, Wei Q, Mills JJ, Tian J, Alvarado J, Sai J, Van Meveren M, South TM, Rietz TA, Zhao B, Moore WJ, Stott GM, Tansey WP, Lee T, Fesik SW..  (2022)  Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.,  65  (8.0): [PMID:35436124] [10.1021/acs.jmedchem.2c00195]

Source